Related Experiment Video
Updated: Jul 14, 2026
05:16
Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage
Published on: August 4, 2021
Recurrent pregnancy loss: the key potential mechanisms
Kwang-Hyun Baek1, Eung-Ji Lee, Yong-Soo Kim
1Graduate School of Life Science and Biotechnology, Cell and Gene Therapy Research Institute, Pochon CHA University, CHA General Hospital, Seoul 135-081, South Korea. baek@cha.ac.kr
Trends in Molecular Medicine
|June 19, 2007
Summary
Recurrent pregnancy loss (RPL) affects 1% of pregnancies. This review explores immunological and thrombophilic factors contributing to unexplained RPL, aiming to guide new treatments.
Area of Science:
- Reproductive immunology
- Genetics and molecular biology
- Obstetrics and gynecology
Background:
- Recurrent pregnancy loss (RPL) affects 0.5%-1% of pregnancies, defined as three or more consecutive miscarriages before 20 weeks.
- While immunological factors are implicated in unexplained RPL, the precise molecular mechanisms remain unclear.
- Recent transcriptomic and proteomic studies suggest various contributing factors.
Purpose of the Study:
- To review the key immunological and thrombophilic mechanisms underlying recurrent pregnancy loss.
- To synthesize current understanding of molecular factors involved in unexplained RPL.
- To provide insights for developing effective RPL therapeutics.
Main Methods:
- Literature review of recent transcriptomic and proteomic studies.
- Analysis of immunological abnormalities associated with RPL.
- Examination of thrombophilic aberrations in RPL.
Main Results:
- Immunological dysfunction is a significant factor in RPL.
- Thrombophilic abnormalities contribute to pregnancy loss.
- Several molecular factors have been identified through advanced '-omics' technologies.
Conclusions:
- Understanding the immunological and thrombophilic mechanisms is crucial for RPL.
- Further research into molecular pathways can lead to targeted therapies.
- This review consolidates current knowledge to advance RPL treatment strategies.
More Related Videos
Related Concept Videos
01:27Ovarian Cycle
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...
01:28Infertility in Females
Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of endometrial...
Endometriosis, a condition characterized by abnormal growth of endometrial...
01:21Nondisjunction
Nondisjunction is the failure of homologous chromosomes or sister chromatids to separate correctly and move to the opposite poles of the cells. This produces daughter cells with abnormal chromosome numbers. Nondisjunction is common during anaphase I or anaphase II of meiosis. Mutations in synaptonemal complex proteins that attach homologous chromosomes increase the chances of nondisjunction in anaphase I of meiosis I. In contrast, mutations in topoisomerases and condensins that hold sister...
01:23Infertility in Males
Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...